ClinicalTrials.gg

Program

TAK-411

A development code.

Its studies are mostly in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, led by Takeda.

Furthest: phase 2, since Jan 23, 20251 company-led study, 1 open or runningNext primary completion: Dec 2, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda11 open or runningphase 2since Jan 23, 2025Jan 23, 2025Dec 2, 2027phase 2 · NCT06798012

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 23, 2025First study: phase 2 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingFirst studyNCT06798012 · 36 planned · United States, Canada, Colombia

Ahead

  1. Dec 2, 2027Primary completion: phase 2 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT06798012

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06798012Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Canada, Colombia2RecruitingDec 2, 202736

How it is read

Names in the registry

  • “TAK-411”, 1 entry

Codes read as this program: TAK411.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.